Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

ANPI.O

ISIN: CA0349181028
SEDOL: 2565325

Rating:

HOLD

Target Price:

0.13 USD

Investment Horizon:

6 to 12 months
30th Dec 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Angiotech Pharmaceuticals Inc’s (Angiotech) NASDAQ common stock price declined significantly in a single trading session, ended 29 December 2008. Nevertheless, our outlook for the company remains unchanged and consequently, we reiterate our HOLD rating for the NASDAQ common stock, even though the target price does not support a HOLD rating at current price levels. Although we anticipate a significant positive currency impact on…

24th Dec 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Angiotech Pharmaceuticals Inc’s (Angiotech) NASDAQ common stock price increased significantly in a single trading session, ended 23 December 2008, primarily due to the purchase of a large stake in the company by top Management of Angiotech. Nevertheless, our outlook for the company remains unchanged and consequently, we reiterate our HOLD rating for the NASDAQ common stock, even though the target price does not support a HOLD rating…

10th Dec 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Angiotech Pharmaceuticals Inc’s (Angiotech) NASDAQ common stock price increased significantly in a single trading session, ended 09 December 2008. Nevertheless, our outlook for the company remains unchanged and consequently we reiterate our HOLD rating for the NASDAQ common stock. Although we anticipate a significant positive currency impact on the Canadian stock over the medium term, we reiterate our HOLD rating for the…

25th Nov 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Angiotech Pharmaceuticals Inc.’s (Angiotech) NASDAQ common stock price achieved our target price on 24 November 2008. We believe this reflects investor concerns over the cancellation of the proposed debt issuance by Angiotech from Ares Management (Ares) and New Leaf Venture Partner (New Leaf) on 21 November 2008. Moreover, our revenue outlook remains modest and we remain concerned over Angiotech’s weak cash position. Consequently…

17th Nov 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Angiotech Pharmaceuticals Inc’s (Angiotech) NASDAQ common stock price increased significantly in a single trading session, ended 14 November 2008. However, our outlook for the company remains unchanged and, consequently, we reiterate our SELL rating for the NASDAQ common stock. We reiterate our HOLD rating for the Canadian stock based on our fundamental outlook ...